Recent Updates
Recently added Catalysts
AMIX Positive Sentiment Score: 75/100

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

Key Takeaway: Autonomix Medical, Inc. has announced the publication of its latest CEO Corner segment, featuring a discussion with CEO Brad Hauser on the recent transaction with RF Innovations, Inc. This partnership involves the licensing of the Apex 6 Radiofrequency Generator's intellectual property. The segment elaborates on how Autonomix aims to transform the diagnosis and treatment of diseases affecting the nervous system with its innovative technology platform. Currently, the company is focusing on developing solutions for pain related to pancreatic cancer, which remains a challenging area in medical treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • The CEO Corner segment highlights recent advancements and collaboration.
  • Licensing the Apex 6 Radiofrequency Generator enhances the company's technology portfolio.
  • The company's unique technology has the potential to revolutionize treatment for various conditions.
  • Initial focus on pain management for pancreatic cancer addresses a critical health issue.

Full Press Release Details

THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discussed the Company’s recently completed transaction with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property to its Apex 6 Radiofrequency Generator.
The CEO Corner segment is now available here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact

Tags

medical device company
innovative technologies

Frequently Asked Questions

What technology does Autonomix Medical focus on?

Autonomix Medical specializes in innovative technologies for diagnosing and treating nervous system diseases.

What is the Apex 6 Radiofrequency Generator?

The Apex 6 Radiofrequency Generator is licensed from RF Innovations for medical applications.

What condition is Autonomix initially targeting?

Autonomix is initially developing technology to treat pain associated with pancreatic cancer.

How sensitive is Autonomix's technology platform?

The technology platform detects neural signals with about 3,000 times greater sensitivity.

Is the technology available for marketing in the US?

No, the technology is investigational and has not been cleared for marketing in the US.

Last updated: Aug 2, 2024